Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)

Sjogren's Syndrome Clinical Trial

Official title:

Patient Phenotypes and Treatment Pathways in Primary Sjogren's Syndrome: an International Cross-sectional Survey of Rheumatologists and Adult Primary Sjögren's Syndrome Patients With Systemic Involvement (Adelphi 2018 pSS Disease Specific Programme)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03501420
• Other study ID #: 207382
• Status: Completed
• Start date: June 13, 2018
• Est. completion date: October 30, 2018

Study information

• Verified date: January 2019
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sjogren's Syndrome is a chronic autoimmune disease characterized by sicca (dryness) symptoms of the mouth and eyes. This autoimmune disease is less commonly studied and there are no licensed treatments to treat the underlying cause of disease and current management is based on clinical experience and/or small clinical studies. This study is based on DSP methodology, a multinational, cross-sectional, multi-sponsor survey of robust real-world data. DSP methodology collects quantitative market research data. The pSS DSP will survey a sample of approximately 230 to 325 rheumatologists and their prospectively consulting pSS subjects in France, Germany, Italy, Spain and the US. The data will be collected via physician interviews, physician workload questionnaires, detailed patient record forms (PRFs) to be completed by physicians, and a self-completion questionnaire by pSS subjects. The data collected using this method includes subjective and objective evidence, clinical information about individual patients, their disease and their treatment. This DSP will follow three key phases: preparatory phase, data collection phase and data processing/analysis phase.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2223
• Est. completion date: October 30, 2018
• Est. primary completion date: October 30, 2018
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Physician eligibility criteria:

• Primary physician specialty identified as Rheumatologist

• Physicians who currently treat 7 or more pSS subjects in a typical month

• Physicians who are actively involved in the management and treatment decisions of pSS subjects

Subject eligibility criteria:

• Subjects with a diagnosis of Sjogren's syndrome in the opinion of the rheumatologist in the absence of Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) or Systemic Sclerosis.

• For main sample (6 subjects per rheumatologist)

• Subjects with age >=18 years and with confirmed diagnosis of pSS and are currently, or have previously, exhibited disease activity in one or more of the categories: fever of non-infectious origin, lymphadenopathy/lymphoma, glandular swelling/enlarged parotid gland, arthralgia/synovitis, erythema/vasculitis/purpura, pulmonary involvement, renal involvement, myositis, peripheral nervous system involvement, central nervous system involvement, cytopenia of autoimmune origin (with neutropenia) and/or anemia and/or thrombocytopenia and/or lymphopenia, hypocomplementemia and/or hypergammaglobulinemia and/or cryoglobulinemia or hypogammaglobulinemia and/or Ever received immunosuppressant or biologic treatment.

• For oversample (1 subject per rheumatologist)

• Subjects with age >=18 years and with confirmed diagnosis of pSS that fit the following criteria: Has never exhibited disease activity in any of the categories above, Moderate or severe fatigue (in the opinion of the rheumatologist)

Exclusion Criteria:

Related Conditions & MeSH terms

• Sjogren's Syndrome
• Syndrome

Intervention

Other:
• Interview
A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
• PSC questionnaire
All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
• PRFs
PRFs will be completed by the physicians for seven of their consulting pSS subjects.

Locations

Country	Name	City	State
United Kingdom	Adelphi Real World Investigational Site	Cheshire

Sponsors (2)

Lead Sponsor	Collaborator
GlaxoSmithKline	Adelphi Real World

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physician reported categorization of pSS subjects	The most common categorization of pSS subjects by rheumatologists will be described, alongside differences in humanistic and clinical burden of these categories.	Baseline
Primary	Statistically derived clusters of pSS subjects	Subject clusters will be statistically derived from demographic, clinical and humanistic characteristics.	Baseline
Secondary	Description of subject's journey	Summary of subject's journeys from diagnosis to current management and treatment, including an overview of HCRU.	As reported
Secondary	Drivers of physician and subject reported satisfaction	Data for drivers of physician and subjects reported satisfaction with disease activity control and symptomatic relief will be derived.	Baseline
Secondary	Level of concordance/discordance between physician and patient reported satisfaction	Data for discordance/concordance between physicians and subjects across key measures will be derived.	Baseline
Secondary	Differences in subjects journey, physician and subjects reported satisfaction amongst the clusters identified in the primary objective	Differences in subjects journey, physician and subjects reported satisfaction amongst the clusters identified in the primary objective will be described.	As reported / Baseline
Secondary	Physician experience of biologic therapy	Physicians' experience of biologic therapy, and attitudes towards biologic therapy for subjects with pSS will be described.	Baseline
Secondary	Physician perception of treatment targets	Physicians' perceptions of treatment targets in pSS will be described.	Baseline
Secondary	subjects attitude towards route of administration	Proportion of subjects willing to take medication by type of administration route (oral/tablet, subcutaneous injection, intravenously) will be described.	Baseline